Can a new biologic clear stubborn psoriasis?

NCT ID NCT07746479

Completed Disease control Sponsor: Livzon Pharmaceutical Group Inc. Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This Phase III trial is testing an investigational biologic called LZM012 in adults with moderate-to-severe plaque psoriasis. The drug targets two inflammatory proteins, IL-17A and IL-17F, to potentially reduce skin symptoms. Participants will receive LZM012 injections, and researchers will measure how many achieve complete skin clearance and improvements in quality of life. The study aims to see if this treatment is effective and safe for this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LZM012, an experimental biologic that blocks IL-17A and IL-17F proteins involved in inflammation
What this could lead to: If successful, LZM012 could offer a new treatment option for people with moderate-to-severe plaque psoriasis, potentially achieving clearer skin and better quality of life.
What could go wrong: This is a single-arm trial without a placebo, so results may be less definitive. As with any biologic, there are risks of side effects, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Locations

Shanghai Dermatology Hospital

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.